Medidon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 13 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.27 M
- Revenue Growth 243.91%
- Profit Growth -736.90%
- Ebitda -667.99%
- Net Worth -8.78%
- Total Assets 50.30%
About Medidon Pharmaceuticals
Medidon Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 February 2020 (Five years 13 days old ). Its registered office is in Patna, Bihar, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.27 M.
Ranjan Kumar and Gunja Devi serve as directors at the Company.
Company Details
- Location
Patna, Bihar, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230BR2020PTC045434
- Company No.
045434
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Feb 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Who are the key members and board of directors at Medidon Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ranjan Kumar  | Director | 11-Feb-2020 | Current |
| Gunja Devi | Director | 11-Feb-2020 | Current |
Financial Performance of Medidon Pharmaceuticals.
Medidon Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 243.91% increase. The company also saw a substantial fall in profitability, with a 736.9% decrease in profit. The company's net worth dipped by a decrease of 8.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medidon Pharmaceuticals?
In 2022, Medidon Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.27 M
₹0
Charges Breakdown by Lending Institutions
- Karnataka Bank Ltd. : 0.03 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Dec 2022 | Karnataka Bank Ltd. | ₹0.27 M | Open |
How Many Employees Work at Medidon Pharmaceuticals?
Unlock and access historical data on people associated with Medidon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medidon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medidon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.